EP1562597A4 - Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration - Google Patents

Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration

Info

Publication number
EP1562597A4
EP1562597A4 EP03781615A EP03781615A EP1562597A4 EP 1562597 A4 EP1562597 A4 EP 1562597A4 EP 03781615 A EP03781615 A EP 03781615A EP 03781615 A EP03781615 A EP 03781615A EP 1562597 A4 EP1562597 A4 EP 1562597A4
Authority
EP
European Patent Office
Prior art keywords
compositions
management
treatment
methods
macular degeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03781615A
Other languages
German (de)
French (fr)
Other versions
EP1562597A2 (en
Inventor
Jerome B Zeldis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of EP1562597A2 publication Critical patent/EP1562597A2/en
Publication of EP1562597A4 publication Critical patent/EP1562597A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Laser Surgery Devices (AREA)
  • Radiation-Therapy Devices (AREA)
EP03781615A 2002-10-31 2003-10-31 Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration Withdrawn EP1562597A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42289902P 2002-10-31 2002-10-31
US422899P 2002-10-31
PCT/US2003/034661 WO2004041190A2 (en) 2002-10-31 2003-10-31 Composition for the treatment of macular degenration

Publications (2)

Publication Number Publication Date
EP1562597A2 EP1562597A2 (en) 2005-08-17
EP1562597A4 true EP1562597A4 (en) 2008-05-14

Family

ID=32312566

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03781615A Withdrawn EP1562597A4 (en) 2002-10-31 2003-10-31 Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration

Country Status (12)

Country Link
EP (1) EP1562597A4 (en)
JP (1) JP2006508950A (en)
KR (1) KR20050061586A (en)
CN (1) CN1732001A (en)
AU (1) AU2003287381B2 (en)
BR (1) BR0315931A (en)
CA (1) CA2504024A1 (en)
MX (1) MXPA05004488A (en)
NZ (1) NZ540186A (en)
TW (1) TWI310312B (en)
WO (1) WO2004041190A2 (en)
ZA (1) ZA200503467B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CN101696205B (en) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(substituted xylylenimine-2-yl)-2,6-dioxopiperidine polymorph and pharmaceutical composition
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP2838879A1 (en) 2012-04-20 2015-02-25 Concert Pharmaceuticals Inc. Deuterated rigosertib
US9643950B2 (en) 2012-10-22 2017-05-09 Concert Pharmaceuticals, Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US20180126273A1 (en) * 2016-11-09 2018-05-10 Agape Assets, LLC Systems and methods for promoting medication adherence

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019649A2 (en) * 1996-11-05 1998-05-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
WO1998054170A1 (en) * 1997-05-30 1998-12-03 Celgene Corporation SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND 1-OXOISOINDOLINES AND METHOD OF REDUCING TNFα LEVELS
WO2000002564A1 (en) * 1998-07-10 2000-01-20 The University Of Sydney Prophylactic treatments of neovascularisation in macular degeneration
WO2001039764A2 (en) * 1999-11-30 2001-06-07 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
US6316471B1 (en) * 1996-07-24 2001-11-13 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US20010056113A1 (en) * 1993-03-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 6-amino EM-12
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
WO2002064083A2 (en) * 2000-11-30 2002-08-22 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
US20020131954A1 (en) * 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
WO2002076926A1 (en) * 2001-02-02 2002-10-03 Schering Corporation 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
WO2003014315A2 (en) * 2001-08-06 2003-02-20 The Children's Medical Center Corporation Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
WO2003097052A2 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2004027027A2 (en) * 2002-09-18 2004-04-01 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1274549B (en) * 1995-05-23 1997-07-17 Indena Spa USE OF FLAVANOLIGNANI FOR THE PREPARATION OF MEDICATIONS FOR ANTI-PROLIFERATIVE ACTIVITY IN CANCER OF THE UTERUS, OVARIAN AND BREAST
CZ295762B6 (en) * 1996-07-24 2005-10-12 Celgene Corporation 2,6-Dioxopiperidines, salts and optical isomers thereof, pharmaceutical compositions containing such compounds and medicaments containing such compounds and intended for reducing TNF-alpha levels
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
ATE418536T1 (en) * 1996-08-12 2009-01-15 Celgene Corp NEW IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN REDUCING CYTOKINE LEVELS
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US6015803A (en) * 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) * 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) * 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
JP2000159761A (en) * 1998-11-30 2000-06-13 Yoshio Takeuchi Fluorothalidomide

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1245229A2 (en) * 1993-03-01 2002-10-02 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
US20010056113A1 (en) * 1993-03-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 6-amino EM-12
US20020119956A1 (en) * 1993-03-01 2002-08-29 D'amato Robert Methods and compositions for inhibition of angiogenesis with phthaloyl glutamic acid derivatives
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
US6316471B1 (en) * 1996-07-24 2001-11-13 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
WO1998019649A2 (en) * 1996-11-05 1998-05-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
WO1998054170A1 (en) * 1997-05-30 1998-12-03 Celgene Corporation SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND 1-OXOISOINDOLINES AND METHOD OF REDUCING TNFα LEVELS
WO2000002564A1 (en) * 1998-07-10 2000-01-20 The University Of Sydney Prophylactic treatments of neovascularisation in macular degeneration
WO2001039764A2 (en) * 1999-11-30 2001-06-07 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
US20020131954A1 (en) * 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
WO2002064083A2 (en) * 2000-11-30 2002-08-22 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
WO2002076926A1 (en) * 2001-02-02 2002-10-03 Schering Corporation 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
WO2003014315A2 (en) * 2001-08-06 2003-02-20 The Children's Medical Center Corporation Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
WO2003097052A2 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2004027027A2 (en) * 2002-09-18 2004-04-01 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AMBRUS J L ET AL: "Study of antiangiogenic agents with possible therapeutic applications in neoplastic disorders and macular degeneration.", JOURNAL OF MEDICINE 2000, vol. 31, no. 5-6, 2000, pages 278 - 282, XP008089946, ISSN: 0025-7850 *
CIULLA T A ET AL: "Changing therapeutic paradigms for exudative age-related macular degeneration: Antiangiogenic agents and photodynamic therapy", EXPERT OPINION ON INVESTIGATIONAL DRUGS 1999 GB, vol. 8, no. 12, 1999, pages 2173 - 2182, XP008014314, ISSN: 1354-3784 *
FINE STUART L ET AL: "Age-related macular degeneration", NEW ENGLAND JOURNAL OF MEDICINE, vol. 342, no. 7, 17 February 2000 (2000-02-17), pages 483 - 492, XP002474933, ISSN: 0028-4793 *
KRUGER A ET AL: "Short-term oral pentoxifylline use increases choroidal blood flow in patients with age-related macular degeneration", ARCHIVES OF OPHTHALMOLOGY, vol. 116, no. 1, January 1998 (1998-01-01), pages 27 - 30, XP002113777, ISSN: 0003-9950 *
MAZUCCO R ET AL: "American Association for Cancer Research - 93rd Annual Meeting. Immunotherapy, chemoprevention and angiogenesis. 6-10 April 2002, San Francisco, CA, USA", IDRUGS, CURRENT DRUGS LTD, GB, vol. 5, no. 5, April 2002 (2002-04-01), pages 408 - 411, XP002371684, ISSN: 1369-7056 *

Also Published As

Publication number Publication date
WO2004041190A3 (en) 2004-09-02
AU2003287381A1 (en) 2004-06-07
NZ540186A (en) 2008-03-28
KR20050061586A (en) 2005-06-22
JP2006508950A (en) 2006-03-16
TW200423936A (en) 2004-11-16
WO2004041190A2 (en) 2004-05-21
EP1562597A2 (en) 2005-08-17
MXPA05004488A (en) 2005-07-26
CN1732001A (en) 2006-02-08
BR0315931A (en) 2005-09-13
ZA200503467B (en) 2006-08-30
AU2003287381B2 (en) 2008-03-06
TWI310312B (en) 2009-06-01
CA2504024A1 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
EP1696910A4 (en) Compositions and methods for treatment of fibrosis
EP1680111A4 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
EP1567158A4 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
EP1635826A4 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
AU2003257937A8 (en) Methods and compositions for treatment of dermal conditions
IL174627A0 (en) Compositions and methods for treatment of burns
IL172194A0 (en) Methods and compositions for treating amyloid-related diseases
EP1567157A4 (en) Methods of using and compositions comprising immunomudulatory compounds for the treatment and management of myeloproliferative diseases
EP1663259A4 (en) Compositions and methods for treatment of cancer
AU2003272450A1 (en) Novel composition and method for treatment of upper respiratory conditions
EP1613266A4 (en) Methods of treating pain and compositions for use therefor
EP1663255A4 (en) Withanamide and withanolide compositions and method of use thereof
EP1567183A4 (en) Methods and compositions for treatment of otitis media
GB0303609D0 (en) Novel therapeutic method and compositions
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
EP1562597A4 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
EP1542664A4 (en) Methods and compositions for treatment of macular and retinal disease
HK1104800A1 (en) Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
GB0324523D0 (en) Compositions and methods of treatment
AU2003297856A1 (en) Oral compositions and methods for treatment of adverse effects or radiation
AU2003259202A8 (en) Compositions and methods for treating and preventing infection
IL166062A0 (en) Compositions and methods for therapeutic treatment
AU2003275433A1 (en) Compositions and methods for treating pain
AU2003225563A8 (en) Compositions and methods for treatment of osteoarthritis
AU2003285883A8 (en) Methods and compositions for determining risk of treatment toxicity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050530

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CELGENE CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 20080414

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 41/00 20060101ALI20080404BHEP

Ipc: A61P 27/02 20060101ALI20080404BHEP

Ipc: A61K 45/06 20060101ALI20080404BHEP

Ipc: A61K 31/454 20060101ALI20080404BHEP

Ipc: A61K 31/00 20060101AFI20080404BHEP

17Q First examination report despatched

Effective date: 20090402

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110208